Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
15.46
-0.62 (-3.86%)
At close: Mar 12, 2026, 4:00 PM EDT
15.43
-0.03 (-0.19%)
After-hours: Mar 12, 2026, 7:58 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
11.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | 860.00K | 117.00K | 15.75% |
| Dec 31, 2019 | 743.00K | -56.35M | -98.70% |
| Jan 31, 2019 | 57.09M | 39.54M | 225.24% |
| Jan 31, 2018 | 17.55M | 14.65M | 505.12% |
| Jan 31, 2017 | 2.90M | - | - |
| Jan 31, 2016 | - | - | - |
| Jan 31, 2015 | - | - | - |
| Jan 31, 2014 | - | - | - |
| Jan 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
SMMT News
- 1 day ago - Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript - Seeking Alpha
- 10 days ago - Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 14 days ago - Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
- 16 days ago - Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - Business Wire
- 23 days ago - Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 - Business Wire
- 5 weeks ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy - Business Wire